Study S002346

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05006885
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 95
Start: 2021-09-30
Primary completion: 2022-08-17
Lead sponsor: Altimmune, Inc.
Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: DRUG:ALT-801; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010888	Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Harrison SA, Journal of hepatology	2025	Randomized trial	PMID 39002641 DOI	cites ClinicalTrials.gov:NCT05006885; registry reference DERIVED:39002641